Radiology, Vol 171, 713-717, Copyright © 1989 by Radiological Society of North America

ARTICLES

Gastrinomas: comparison of MR imaging with CT, angiography, and US

H Frucht, JL Doppman, JA Norton, DL Miller, AJ Dwyer, JA Frank, R Vinayek, PN Maton and RT Jensen
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892.

In this prospective study, magnetic resonance (MR) imaging was used to localize gastrinoma in 24 patients with Zollinger-Ellison syndrome. The results were confirmed by means of either surgery or percutaneous liver biopsy and compared with results of computed tomographic (CT) scanning, selective abdominal angiography, and abdominal ultrasound (US). For primary extrahepatic gastrinoma (intra-or extrapancreatic), MR imaging had a sensitivity of 20% and a specificity of 100%, with a positive predictive value of 100% and a negative predictive value of 11%. For metastatic gastrinoma in the liver, MR imaging had a sensitivity of 43% and a specificity of 100%, with a positive predictive value of 100% and a negative predictive value of 81%. The ability of MR imaging to depict extrahepatic gastrinomas was directly related to tumor size; no tumors smaller than 1 cm were detected, and 50% of tumors 3 cm or larger were detected. MR imaging was as effective as abdominal US but less effective than either CT scanning or selective abdominal angiography for the detection of extrahepatic gastrinoma. In seven patients with hepatic gastrinoma, three gastrinomas were detected with MR imaging and with abdominal US, while five were detected with CT scanning and with selective abdominal angiography. These results indicate that, at the present time, MR imaging is generally not useful in the initial attempt to localize gastrinomas.

This article has been cited by other articles:

				M. J. Berna, B. Annibale, M. Marignani, T. V. Luong, V. Corleto, A. Pace, T. Ito, D. Liewehr, D. J. Venzon, G. Delle Fave, et al. A Prospective Study of Gastric Carcinoids and Enterochromaffin-Like Cell Changes in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Identification of Risk Factors J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1582 - 1591. [Abstract] [Full Text] [PDF]

				K. K. Kazanjian, H. A. Reber, and O. J. Hines Resection of Pancreatic Neuroendocrine Tumors: Results of 70 Cases Arch Surg, August 1, 2006; 141(8): 765 - 770. [Abstract] [Full Text] [PDF]

				K. M. Hoffmann, F. Gibril, L. K. Entsuah, J. Serrano, and R. T. Jensen Patients with Multiple Endocrine Neoplasia Type 1 with Gastrinomas Have an Increased Risk of Severe Esophageal Disease Including Stricture and the Premalignant Condition, Barrett's Esophagus J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 204 - 212. [Abstract] [Full Text] [PDF]

				T. Ichikawa, M. S. Peterson, M. P. Federle, R. L. Baron, H. Haradome, Y. Kawamori, S. Nawano, and T. Araki Islet Cell Tumor of the Pancreas: Biphasic CT versus MR Imaging in Tumor Detection Radiology, July 1, 2000; 216(1): 163 - 171. [Abstract] [Full Text]

				R. F. Thoeni, U. G. Mueller-Lisse, R. Chan, N. K. Do, and P. B. Shyn Detection of Small, Functional Islet Cell Tumors in the Pancreas: Selection of MR Imaging Sequences for Optimal Sensitivity Radiology, February 1, 2000; 214(2): 483 - 490. [Abstract] [Full Text]

				J. F. London, H. Frucht, J. L. Doppman, P. N. Maton, J. D. Gardner, and R. T. Jensen Zollinger-Ellison Syndrome in the Intensive Care Setting J Intensive Care Med, November 1, 1989; 4(6): 272 - 283. [Abstract] [PDF]